Vilazodone Treatment for Marijuana Dependence
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Psychiatric |
| Therapuetic Areas: | Psychiatry / Psychology |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 4/21/2016 |
| Start Date: | August 2012 |
| End Date: | March 2016 |
Marijuana is the most commonly used illicit drug, yet few clinical trials have evaluated
pharmacotherapy treatments for marijuana dependence. This study will evaluate the efficacy
of vilazodone for reducing marijuana use in marijuana-dependent adults. A contingency
management intervention (CM)and motivational enhancement therapy (MET)will be incorporated
to encourage study engagement and retention, and genomic DNA will be extracted to
characterize subjects according to polymorphisms of genes potentially relevant to the
activity of vilazodone. It is hypothesized that vilazodone combined with MET and CM will
reduce the percent of marijuana-positive urine drug screen results in marijuana-dependent
individuals as compared to a placebo treatment combined with MET and CM.
pharmacotherapy treatments for marijuana dependence. This study will evaluate the efficacy
of vilazodone for reducing marijuana use in marijuana-dependent adults. A contingency
management intervention (CM)and motivational enhancement therapy (MET)will be incorporated
to encourage study engagement and retention, and genomic DNA will be extracted to
characterize subjects according to polymorphisms of genes potentially relevant to the
activity of vilazodone. It is hypothesized that vilazodone combined with MET and CM will
reduce the percent of marijuana-positive urine drug screen results in marijuana-dependent
individuals as compared to a placebo treatment combined with MET and CM.
The purpose of this study is to determine if the medication vilazodone is effective in
helping frequent marijuana smokers cut down or stop using marijuana. Vilazodone is FDA
approved for the treatment of depression- in this study, vilazodone's effect on marijuana
dependence is being investigated.
Participation in the study takes 10 visits over a period of approximately two to three
months. The first visit is a screening visit to determine if participants are eligible to
participate. After the initial assessment visit, the weekly visits take about 30 minutes,
with the exception of three therapy sessions which take approximately 60-90 minutes. The
three therapy sessions will focus on participant's marijuana use and reasons they may have
for stopping or cutting down on use. After completing an initial therapy session,
participants will be randomly selected to receive the study medication, either vilazodone or
placebo (a capsule that does not contain any active medication). Participants will have
weekly study visits with a clinician. At each study visit, they will be asked to fill out
forms and answer specific questions concerning their substance use, anxiety symptoms, and
feelings in general. They will be providing urine samples to check for illegal drugs of
abuse including marijuana and other drugs. They will also have blood samples drawn during to
determine if you are taking the medication as directed.
helping frequent marijuana smokers cut down or stop using marijuana. Vilazodone is FDA
approved for the treatment of depression- in this study, vilazodone's effect on marijuana
dependence is being investigated.
Participation in the study takes 10 visits over a period of approximately two to three
months. The first visit is a screening visit to determine if participants are eligible to
participate. After the initial assessment visit, the weekly visits take about 30 minutes,
with the exception of three therapy sessions which take approximately 60-90 minutes. The
three therapy sessions will focus on participant's marijuana use and reasons they may have
for stopping or cutting down on use. After completing an initial therapy session,
participants will be randomly selected to receive the study medication, either vilazodone or
placebo (a capsule that does not contain any active medication). Participants will have
weekly study visits with a clinician. At each study visit, they will be asked to fill out
forms and answer specific questions concerning their substance use, anxiety symptoms, and
feelings in general. They will be providing urine samples to check for illegal drugs of
abuse including marijuana and other drugs. They will also have blood samples drawn during to
determine if you are taking the medication as directed.
Inclusion Criteria:
- Must meet DSM-IV criteria for marijuana dependence
- Must be between the ages of 18 and 65 years old
- If female and of childbearing potential, must agree to use acceptable method of birth
control for duration of the trial.
- Cannabis-positive urine drug screen at screening
- Must consent to random assignment
- Must be able to read and provide informed consent
Exclusion Criteria:
- Women who are pregnant, nursing, or plan to become pregnant during course of study
- Must not have a history of or current psychotic disorder, bipolar disorder, or eating
disorder
- Must not pose a current suicidal or homicidal risk
- Must not have evidence or history of serious medical disease
- Must not require concomitant therapy with psychotropic medication or CYP3A4
inhibitors
- Must not be currently dependent on other substances, with the exception of nicotine;
- Patients who, in the investigator's opinion, would be unable to comply with study
procedures or assessments
We found this trial at
1
site
171 Ashley Avenue
Charleston, South Carolina 29425
Charleston, South Carolina 29425
843-792-1414
Medical University of South Carolina The Medical University of South Carolina (MUSC) has grown from...
Click here to add this to my saved trials
